Nearly six months into the epidemic, only 23.48% of the people are affected in Delhi, Sero-prevalence study conducted by NCDC  

Total coronavirus cases rise to 315 in India, Maharashtra shoot to 63

New Delhi I Nearly six months into the epidemic, only 23.48% of the people are affected in Delhi, which has several pockets of dense population. This information has been revealed through a survey. The Ministry of Health and Family Welfare [MoHFW] commissioned a sero-surveillance study in Delhi.This study has been done by the National Center for Disease Control [ NCDC] in collaboration with Govt of National Capital Territory of Delhi, following a rigorous multi-stage sampling study design.

Study was conducted from 27th of June 2020 to 10th July 2020.

For all the 11 districts of Delhi, survey teams were formed. Blood samples were collected from selected individuals after taking written informed consent and then their sera were tested for IgG antibodies and infection using COVID KAVACH ELISA approved by Indian Council for Medical Research [ICMR]. It is one of the largest sero-prevalence studies conducted in the country using the ELISA testing.

21,387 samples were collected as per lab standards and were tested. The tests done help in identification of presence of antibodies in the general population. These test performed is not a diagnostic test but only provides information about past infection due to SARSCoV-2 in individuals who test positive.

Antibody testing repeatedly done over time i.e. sero-surveillance, generates important evidence for assessing the spread of the pandemic from time to time.

CSIR-CMERI, Durgapur, unveils the COVID Protection System (COPS) for Workplace

The results of the sero-prevalence study show that on an average, across Delhi, the prevalence of IgG antibodies is 23.48 %.  The study also indicates that a large number of infected persons remain asymptomatic. This implies the following:

Nearly six months into the epidemic, only 23.48% of the people are affected in Delhi, which has several pockets of dense population. This can be attributed to the proactive efforts taken by the Government to prevent the spread of infection including prompt lockdown, effective containment and surveillance measures, including contact tracing and tracking, as well as citizen’s compliance to COVID Appropriate Behaviours.

India’s 1st COVID-19 Vaccine -COVAXIN, gets DCGI approval for Phase I & II Human Clinical Trials

However, a significant proportion of the population is still vulnerable. Therefore, the containment measures need to continue with the same rigour. Non-pharmacological interventions such as physical distancing, use of face mask/cover, hand hygiene, cough etiquette and avoidance of crowded places etc., must be followed strictly.